Answers are grounded in this paper and cite their sources.
Background We examined identifiable vaginal estradiol acquisition, patient payments, and sociodemographic differences among US women aged 55 years and older. Methods We analyzed repeated cross-sectional MEPS data for 2017–2023. Identifiable vaginal estradiol was designated as the principal cross-year outcome during revision because conjugated estrogen cream was not specifically identifiable after 2020. The study was not preregistered. Survey-weighted estimates and identically specified spending models were reported for 2017–2023 and 2020–2023. Payments were expressed in 2023 US dollars. Results The sample comprised 34,086 person-years from 17,757 women, including 483 estradiol user-years. Acquisition was 1.35% in 2017 and 2.33% in 2023 (adjusted OR per year, 1.15; 95% CI, 1.08–1.22). Mean annual patient payments among estradiol users were $217 in 2017 and $106 in 2023. For 2017–2023, unadjusted and adjusted slopes were −19.53 (95% CI, −34.69 to −4.37) and −18.97 (−33.33 to −4.60) USD per year; corresponding 2020–2023 slopes were −3.73 (−27.61 to 20.14) and −4.66 (−29.22 to 19.90). Pooled acquisition was 0.79% below 200% FPL and 2.54% at or above 400% FPL. Conclusions Recorded vaginal estradiol acquisition was higher in 2022–2023 than in earlier years and differed by income. Mean annual patient payments among women with recorded acquisitions declined over 2017–2023, although the post-2020 OOP trend was uncertain. Public-file identification limits inference about total vaginal estrogen acquisition, GSM treatment coverage, and affordability.
No takes yet. Share an insight, caveat, or question.
Chen et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: